NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
GENNEX LABORATORIES LTD. (BSE: 531739)
531739 Technical Analysis
1.5
As on 24th Dec 2024 531739 SHARE Price closed @ 16.02 and we RECOMMEND Buy for LONG-TERM with Stoploss of 14.80 & Sell for SHORT-TERM with Stoploss of 16.19 we also expect STOCK to react on Following IMPORTANT LEVELS. |
531739SHARE Price
Open | 16.69 | Change | Price | % |
High | 16.69 | 1 Day | -0.35 | -2.14 |
Low | 15.86 | 1 Week | 0.93 | 6.16 |
Close | 16.02 | 1 Month | 0.93 | 6.16 |
Volume | 438334 | 1 Year | -0.18 | -1.11 |
52 Week High 21.89 | 52 Week Low 13.90 |
BSE INDIA Most Active Stocks
532822 | 7.47 | -0.13% |
532411 | 0.41 | 0.00% |
517001 | 0.09 | 12.50% |
511700 | 1.01 | -0.98% |
512149 | 0.88 | 0.00% |
511389 | 7.25 | -2.42% |
534690 | 7.65 | 4.79% |
532775 | 2.04 | -0.97% |
531328 | 1.05 | 0.96% |
532648 | 19.80 | -0.60% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
531739 Daily Charts |
531739 Intraday Charts |
Whats New @ Bazaartrend |
531739 Free Analysis |
|
531739 Important Levels Intraday
RESISTANCE | 17.62 |
RESISTANCE | 17.11 |
RESISTANCE | 16.79 |
RESISTANCE | 16.47 |
SUPPORT | 15.57 |
SUPPORT | 15.25 |
SUPPORT | 14.93 |
SUPPORT | 14.42 |
531739 Target April 2025
4th UP Target | 0 |
3rd UP Target | 0 |
2nd UP Target | 0 |
1st UP Target | 0 |
1st DOWN Target | 0 |
2nd DOWN Target | 0 |
3rd DOWN Target | 0 |
4th DOWN Target | 0 |
531739 Weekly Target
4th UP Target | 0.00 |
3rd UP Target | 0.00 |
2nd UP Target | 0.00 |
1st UP Target | 0.00 |
1st DOWN Target | 0.00 |
2nd DOWN Target | 0.00 |
3rd DOWN Target | 0.00 |
4th DOWN Target | 0.00 |
531739 Target2025
4th UP Target | 41.96 |
3rd UP Target | 33.89 |
2nd UP Target | 28.91 |
1st UP Target | 23.92 |
1st DOWN Target | 9.7 |
2nd DOWN Target | 4.71 |
3rd DOWN Target | -0.27 |
4th DOWN Target | -8.34 |
GENNEX LABORATORIES LTD. ( BSE INDIA Symbol : 531739 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
531739 Other Details
Segment | EQ | |
Market Capital | 473121216.00 | |
Sector | Healthcare | |
Industry | Drugs - Generic | |
Offical website | > echo $website ; ?> |
531739 Address
![]() |
531739 Latest News
531739 Business Profile
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India. Address: Plot No. 144, Akash Ganga, Hyderabad, India, 500073
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service